<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03185156</url>
  </required_header>
  <id_info>
    <org_study_id>WESTCHINASUHA-023</org_study_id>
    <nct_id>NCT03185156</nct_id>
  </id_info>
  <brief_title>The Preventive Effects of Sub Hypnotic Dose of Propofol for Nausea and Vomiting Induced by Hemabate</brief_title>
  <official_title>The Preventive Effect of Sub Hypnotic Dose of Propofol for Nausea and Vomiting Induced by Hemabate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Second University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Second University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled trail, the objective of this study is observation
      the effect of sub hypnotic dose of propofol for prevention of nausea and vomiting induced by
      hemabate during spinal anesthesia for elective cesarean section. The primary outcome is the
      presence of post-delivery intra-operative nausea and vomiting in parturients. The patients
      demographic characteristics, blood pressure, sensory block level, and the medications will be
      collected.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2017</start_date>
  <completion_date type="Actual">January 30, 2018</completion_date>
  <primary_completion_date type="Actual">January 29, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>60 maternal aged 20-40 years will be collected</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The presence of nausea and vomiting</measure>
    <time_frame>24 hours</time_frame>
    <description>the patients were not asked directly about nausea during the course of the surgery, but its incidence was recorded when spontaneously reported vomiting was recorded as observed by investigator</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>propofol group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>first dose 0.3mg/Kg propofol, then 1mg/Kg/hr micro-pump</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>first dose 0.03ml/Kg normal saline, then 0.1ml/Kg/hr micro-pump</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>first dose 0.3mg/Kg propofol, then 1mg/Kg/hr micro-pump</description>
    <arm_group_label>propofol group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>first dose 0.03ml/Kg placebo saline, then 0.1ml/Kg/hr micro-pump</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 20-40 years;

          -  American Standards Association status I-II.

        Exclusion Criteria:

          -  Patients with allergy or hypersensitivity to propofol, lipid emulsion, or granisetron;

          -  History of nausea or vomiting within 24h before cesarean delivery;

          -  History of gastrointestinal or psychiatric disease, motion sickness, smoking,
             postoperative nausea and vomiting;

          -  Morbid obesity;

          -  Consumption of drugs such as opioids, antiemetics , H2 antagonists, phenothiazines
             and/or corticosteroids within 24h before the study period;

          -  Any chronic medical or surgical disorders complicating the pregnancy;

          -  Conditions contraindicating regional anesthesia.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West China Second University Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>June 10, 2017</study_first_submitted>
  <study_first_submitted_qc>June 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>October 21, 2018</last_update_submitted>
  <last_update_submitted_qc>October 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Second University Hospital</investigator_affiliation>
    <investigator_full_name>Yanmei-Bi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>nausea and vomiting</keyword>
  <keyword>hemabate</keyword>
  <keyword>propofol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>published in paper form</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

